M. González-Fernández

Persistence of biological agents over an eight-year period in rheumatoid arthritis and spondyloarthritis patients.

E. Villamañán, A. Balsa, A. Herrero, 2019, Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria.

Polyarteritis Nodosa Resistant to Conventional Treatment in a Pediatric Patient

J. García-Consuegra, M. González-Fernández, 2007, The Annals of pharmacotherapy.

Analysis of antiretroviral therapy modification in routine clinical practice in the management of HIV infection

I. Jiménez-Nácher, J. González-García, F. Moreno-Ramos, 2016, European journal of hospital pharmacy. Science and practice.

Cost evolution of biological agents for the treatment of spondyloarthritis in a tertiary hospital: influential factors in price

F. Gayá, E. Villamañán, C. Plasencia, 2018, International Journal of Clinical Pharmacy.

Evaluation of the registry DIALYREG for the assessment of continuous renal replacement techniques in the critically ill patient

M. Herrera-Gutiérrez, J. Barea-Mendoza, J. Sánchez-Izquierdo Riera, 2023, Scientific reports.

SAT0565 COST EVOLUTION OF BIOLOGICAL AGENTS FOR THE TREATMENT OF RHEUMATOID ARTHRITIS IN A TERTIARY HOSPITAL INFLUENTIAL FACTORS IN PRICE

C. Plasencia, A. Balsa, I. Jiménez-Nácher, 2019, Saturday, 15 June 2019.

Real-world Performance of a New Strategy for Off-Label Use of Guselkumab in Moderate to Severe Psoriasis: Super-Responder Patients as the Epitome of Efficacy and Optimisation

A. Herrero-Ambrosio, A. Mayor-Ibarguren, M. González-Fernández, 2023, Clinical drug investigation.